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TheJapanesetraditionalherbalmedicine,Kampo,hasgraduallyreemerged and148diﬀerentformulations(mainlyherbalextracts)
can be prescribed within the national health insurance system. The objective of this article is to introduce Kampo and to present
information from previous clinical studies that tested Kampo formulae. In addition, suggestions on the design of future research
will be stated. The literature search was based on a summary, up until January 2009, by the Japanese Society of Oriental Medicine
and included only those trials which were also available in either Pubmed or ICHUSHI (Japan Medical Abstracts Society). We
included 135 studies, half of these studies (n = 68) used a standard control and 28a placebo control. Thirty-seven trials were
publishedinEnglish[allrandomizedcontrolledtrials(RCTs)]andtheremainingarticleswere inJapaneseonly.Thesamplesizefor
moststudieswassmall(two-thirdofthestudiesincludedlessthan100patients)andtheoverallmethodologicalqualityappeared to
be low. None of the studies used Kampo diagnosis as the basis for the treatment. In order to evaluate Kampo as a whole treatment
system, certain aspects should be taken into account while designing studies. RCTs are the appropriate study design to test eﬃcacy
or eﬀectiveness; however, within the trial the treatment could be individualized according to the Kampo diagnosis. Kampo is a
complex and individualized treatment with a long tradition, and it would be appropriate for further research on Kampo medicine
to take this into account.
1.Background
1.1. Historical Background. Japanese traditional herbal
medicine (Kampo medicine) obtained the unique features
observed today during its phase of long historical develop-
ment in Japan. In Japan, the administration of crude herbal
drug formulations dates back by more than 1500 years.
Recent decades have seen a revival of Kampo medicine in
medical practice, accompanied by a scientiﬁc reevaluation
and critical examination of its relevance in modern health
care [1].
The term “Kampo”, which literally means “method from
the Han period (206 BC to 220 AD) of ancient China”,
refers to its origin from ancient China. The basic therapeutic
handbook for the application of herbal prescriptions was
the Shang han lun. During the Edo-period from 1600
onwards, the speciﬁc Japanese characteristics of Kampo
took shape. The seclusion of Japan from the outside world
led to ever increasing diﬀerences from the predominantly
C h i n e s ec o n c e p t s .T h eh u g ev a r i e t yo ft h et h o u s a n d so f
Chinese crude drugs was reduced to ∼300, those being the
most eﬃcacious drugs which were subsequently combined
into ∼300 prescriptions. From a pragmatic point of view,
Japanese physicians criticized the highly theoretical and
speculative nature of Chinese medicine as being inadequate
to meet the problems of every-day practice. The strongest
critique came from Yoshimasu Todo in the 18th century
who wrote: “In clinical medicine, we should only rely on
what we actually have observed by examination of the
patient”. For Yoshimasu Todo, one way to gain data on2 Evidence-Based Complementary and Alternative Medicine
the condition of the body was to examine the abdomen, for
which he developeda reﬁned palpation technique (fukushin)
[2]. The results of the abdominal palpation should give
additional clinical information in order to select the most
appropriate herbal prescription for the patient. Yoshimasu
Todo’s pragmatic attitude and his abdominal palpation as a
diagnostic procedure has had a strong inﬂuence on Kampo
therapy right up until the present day [3].
It is not surprising that many Japanese physicians were
drawn towards medical techniquesfromthe West to improve
their therapeutic options in surgery, but most of them con-
tinued to use traditional Kampo prescriptions for treating
problems of internal medicine until the 19th century. At
the end of the 19th century, it became obvious that for the
urgentmedicalproblemsofthattime,infectiousdiseasesand
acute surgical problems, Western medicine had better tools.
The German system of medical education was adopted. In
1876, the government passed a regulation that all physicians
were required to study Western medicine. The practice of
Kampowasnotforbiddenbutgreatlyinhibitedandgradually
declined [4]. However, after the Second World War, the
ﬁrst modern Kampo specialists carried on the traditions
from the Edo-period. This revival of Kampo took place
within a context dominated by modern Western medicine.
The pragmatic and reductive approach of restricting Kampo
therapy to clinically meaningful components helped to
facilitate its gradual integration into modern medicine.
Modern industrial society, in combination with longer life
expectancy, has caused a shift in the predominant disease
patterns, bringing to the therapeutic forefront chronic
and degenerative diseases, functional and psychosomatic
disorders and the multimorbidity of the elderly. These
provide the main indications for the use of herbal drugs,
not only with respect to treatment, but also for prevention
[5].
Although rooted in Chinese tradition, Kampo medicine
is not the same as modern traditional Chinese medicine
(TCM). TCM emphasizes the traditional concepts of East
Asian natural philosophy, such as Yin and Yang and the the-
ory of the ﬁve elements. Japanese Kampo favors diagnostic
methods that directly relate the symptoms to the therapy,
bypassing speculativeconcepts.The vastarray ofcrudedrugs
has been reduced in Kampo and also the quantity of each
drug in the formulation is much lower. While Kampo still
uses traditional prescriptions, TCM also tends to create new
drug combinations [6].
1.2. Usage and Integration into Modern Medicine. Kampo
traditional prescriptions have been included in the Japanese
National Health Insurance drug list since 1971. A total
of 148 Kampo herbal prescriptions are able to be funded
to date. The application of Kampo has steadily increased
and according to a survey by the Journal Nikkei Medical,
more than 70% of physicians prescribe Kampo drugs today
[7]. The Japan Society for Oriental Medicine is the biggest
society for Kampo medicine and has 8600 members and
2600 certiﬁed board members. In 2001, Kampo education
for medical students was incorporated into ‘the model core
curriculum’ by the Japanese Ministry of Education, Culture,
Sports, Science and Technology [6].
The development of modern ready-to-use forms was
directly related to the enormous increase in Kampo usage,
mainly as spray-dried granular extracts of the original
formulae. They have increasingly replaced the traditional
decoction of the crude drugs, even though they are also
covered by the national insurance system. Besides being
simple to administer, industrial production has enabled
several other advantages. The quality control of the purity
as well as toxicity is standardized in Japan, following
the Japanese pharmacopoeia and internationally established
regulations for Good Manufacturing Practice (GMP) and
Good Laboratory Practice (GLP). The standardization of
the main components has become possible and this is a
precondition of clinical research. Today, extract preparations
make up to 95% of the Japanese Kampo market.
In Western countries, herbal therapies originating in
other cultural areas, mainly Chinese herbal medicine as
part of TCM, are receiving increasing interest. In the
USA, TCM is still far more visible than Kampo. The
practitioners practice herbal therapy often in combination
with acupuncture, which is often a mixture of Chinese,
Japanese and Korean acupuncture styles. Kampo drugs are
only available over the counter, meeting Japanese GMP
criteria. Since Japanese pharmaceutical companies have
started clinical trials in the USA, several drugs have already
been registered as investigational new drugs (IND) by the
Food and Drug Administration. Safety and toxicity data
from Japan are generally accepted by the US and European
agencies.
In Europe, especially in Germany, there is a long-term
tradition of herbal medicine, and there is growing interest
in Chinese phytotherapy and Japanese Kampo is also getting
more and more attention. However, there is a shortage of
doctors specialized in Japanese Kampo.
1.3. Background of Kampo. Kampo is an individualized
treatment system where the overall condition of the patient
and their constitution are of real importance; additionally,
Kampo has a holistic therapeutic approach, as the mind
and body are seen as one entity. The therapeutic aim is
to relieve symptoms and to restore harmony in bodily
functions. The treatment regime is based on symptoms. For
the determinationofthe appropriateherbal prescription, the
physician carries out a thorough investigation of the com-
plaints and symptoms of the patient, including taking their
temperature, examining sensation, weakness or sweating,
symptoms which are not often primarily taken into account
inconventionalmedicine.Thephysicalexamination includes
abdominal palpation,tongueinspection and pulse diagnosis.
This provides additional information concerning the state
of the disease, by gathering the amount and distribution of
ki (vital energy), ketsu (blood) and sui (body ﬂuid). The
subjective complaints and the symptoms observed by the
physician are combined to an individual symptom proﬁle, a
Kampo diagnosis (sho), which leads to the selection of the
appropriate prescription [8]. It may happen that patientsEvidence-Based Complementary and Alternative Medicine 3
Table 1: Summary of Kampo clinical studies (1987–2007).
RCT Quasi-RCT Cross-over design Comparative study
(non-randomized) Total
Kampo versus either no
treatment or a diﬀerent
Kampo formula
31 1 4 3 39
Kampo versus placebo 22 0 2 4 28
Kampo versus standard
treatment 53 5 4 6 68
Total 106 6 10 13 135
with the same conventional diagnosis obtain diﬀerent pre-
scriptions (same diagnosis but diﬀerent treatments), or
patientswith diﬀerentconventional diagnoses are prescribed
the same formula (same treatment for diﬀerent diagnoses).
Japanese physicians with limited education in Kampo
diagnostics tend to apply the formulations according to
conventional Western diagnoses. This makes sense for some
limited indications, if the formula for the Kampo sho is close
to the conventional diagnosis. However, in most cases, the
traditional individual approach, where each patient receives
their appropriate prescription, is the preferred option. For
example,diseasesthatareexpectedtorespondtotheformula
Kakkonto are diagnosed as Kakkonto-sho and it naturally
follows that Kakkonto is prescribed in such cases.
These special conditions have made clinical research in
theﬁeldof Kampo medicinemore complexthan theresearch
onconventionaldrugs. TheWorld HealthOrganization West
Paciﬁc Regional Oﬃce (WHO/WPRO) has put considerable
eﬀorts into standardizing East Asian traditional medicine
[9]. WHO headquarters is considering incorporating the
international classiﬁcation of Traditional Medicine, East Asia
(ICTM EA) into International Classiﬁcation of Diseases
(ICD)-11. ICD-11 is planned to be ﬁnalized in 2014 and
scheduled to be approved by the WHO assembly in 2015.
Japan proposes a double coding system of the ICD codes,
that is, the conventional diagnosis code together with the
traditional diagnosis (or pattern) code. This will allow
integration into the conventional medical system without
loosing the traditional information. The Kampo pattern
(sho) codes have already been published in Japanese [10].
2.InformationAvailableonClinicalResearch
Our search was based on an evidence report of Kampo
treatment madebytheJapanese SocietyofOrientalMedicine
(JSOM) which included 320 clinical trials between 1986 and
2008. [11]. This report includesKampo trials available in the
Cochrane register [12], ICHUSHI (Japan Medical Abstracts
Society) [13] and the database from the Japan Kampo
Medicines Manufacturer Association [14]. In this review
only those studies were included, which used granulate
formulations and were based on the drug regulation that
was introduced in 1986. Liquid formulations and decoctions
were excluded. Only peer-reviewed research from the JSOM
databasewere included,which were also availableinPubMed
[15] or ICHUSHI [13]. A total of 135 trials, published
between 1988 and 2007, were identiﬁed and summarized
Table 1.These publicationswereextracted bytworesearchers
ﬂuent in both English and Japanese. Subsequently, they were
discussed with two senior researchers (a Kampo specialist
from Japan and a research methodologist from Germany).
We classiﬁed Kampo clinical studies into three categories
(Tables 2, 3,a n d4):
(i) Kampo compared with either no treatment or diﬀer-
ent Kampo formula.
(ii) Kampo compared with placebo.
(iii) Kampo compared with standard treatment.
Among the 135 clinical studies, 106 were randomized
controlled trials (RCTs), 6 quasi-RCTs and 10 were cross-
over studies. There were 13 non-randomized comparative
studies. Among the 106 RCTs, 23 studies were placebo-
controlled. More than two thirds of the studies used only
Kampo as verum, whereas in 38 studies, Kampo was used
in addition to the standard treatment. Almost half of the
studies (n = 68) used a standard control, 28 used a placebo
control, 24 had no treatment control and in 15, another
Kampo formula was used as a control Table 1.
The sample size varied between 4 patients in the smallest
study and 2069 patients in the largest. Most of the studies
were small. Two thirds included less than 100 patients
and the overall quality was low. Thirty-ﬁve trials were
published in English and the remaining studies were in
Japanese. The spectrum of diagnoses was diverse. The most
common diagnosis was asthma (ICD J 45.0 and J 45.9),
which was evaluated in nine studies. Many of the trials had
low methodological quality (small sample size and unclear
concealment) and thus a publication bias is to be expected.
With respect to the methodology, it is interesting to note
that in all studies summarized here, the treatment was based
on the Western diagnosis only. A Kampo diagnosis was not
mentioned in any of the trials. However, one trial seemed
to be more individually based, using seven diﬀerent Kampo
formula in the verum group [134].
3.SuggestionsforFutureResearch
3.1. Relevant Research Questions. The research available
followed a Western approach and concentrated on single
Western diagnoses treated with one Kampo formula. Since
Kampo is a comprehensive and complex treatment system4 Evidence-Based Complementary and Alternative Medicine
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with a traditional approach, many research questions still
need to be investigated. Kampo has been used for hundreds
of years and is well integrated into the Japanese health
care system, therefore it should be taken into account using
an appropriate research strategy. When performing clinical
research identical questions must be addressed for every new
treatment, as well as for traditional treatments, which are
already on the market:
(i) For whom and what is it used to treat?
(ii) Is it safe?
(iii) Is it superior to placebo?
(iv) Is it superior or equivalent to conventional standard
treatment?
For traditional treatments, the order of research ques-
tions should diﬀer from conventional drug research, because
traditional treatments are already widely available [150].
First, knowledge is needed regarding who will beneﬁt from
the treatment and which diseases the treatment is intended
to treat, as well as how it is to be administered. In addition, it
would be helpful to get an idea as to whether the patients
improve under the treatment not to mention the essential
safety assessment.
All of these questions could be answered using a
prospectiveobservationalstudywhichevaluatestheseaspects
in usual care. This has been done for other traditional
treatments such as homeopathy [151–153], and is cur-
rently being carried out for Kampo at the Keio University
[154].Thiscomputer-basedself-assessment systemisdivided
into two domains. One is the patients’ self-assessment at
every visit using a visual analogue scale (VAS) and the
other domain is an assessment by the physician. Data
from both sources are combined and analyzed using data
mining. The advantage of this system is that data is
collected in a real-life setting. Also, Kampo values subjective
complaints. This computer-based, self-assessment system,
allows data incorporation of patient’s subjective outcome
measures.
Objective outcome measures which are often used in
experimental RCTs are sometimes separated from subjective
feelings. Kampo physicians value subjective complaints and
diagnose sho not only based on objective ﬁndings, but also
fromthesubjectivecomplaints.TheevaluationoftheKampo
treatmentbythephysicianissometimesdecidedbasedonthe
subjective symptoms. Current Kampo clinical research has
not taken this aspect into account. Due to the individualized
treatment approach of Kampo, subjective outcome measures
are relevant and should always be considered while planning
a study. In addition to databases, some authors have also
suggestedthatmoreindividualsingle-caseresearch including
N of one trials would be suitable to reﬂect Kampo medicine
[155, 156]. The main motivation to perform clinical research
on traditional treatments is for justiﬁcation purposes, most
placebo-controlled trials on Kampo do not reﬂect the use of
Kampo in usual practice and are therefore not helpful when
making medical decisions in daily practice.
3.2. Testing for Superiority over Placebo. Previous research
has followed the principles of conventional drug research
by testing the superiority of a single Kampo formula over a
placebo for a clearly deﬁned conventionaldiagnosis. An RCT
from 1998, for example, compared Rikkunshito with a kind
of placebo (low dose of the same formula) for the treatment
of dyspepsia [68]. Results from this kind of trial are helpful
for the integration of a single formula into conventional
care. A formula that has proven eﬃcacy in a conventional
drug trial could be used in the future without any Kampo
knowledge. However, this provides no information about
Kampo as a whole treatment system.
Nevertheless, this kind of research does not represent
the traditional Kampo treatment. A traditional treatment is
led from the Kampo diagnosis (by taking a patient history,
abdominal examination, tongue and pulse diagnosis). If the
aim of a clinical trial is to ask whether Kampo treatment in a
traditional way iseﬃcaciousornot,thetraditional treatment
system has to be taken into account. For this purpose, an
additional Kampo diagnosis with the conventional diagnosis
couldbeusedforchoosing theappropriateKampomedicine.
There are two options; the ﬁrst excludes the inﬂuences of
the Kampo diagnostic procedure and the study could be
performed in a similar way as suggested for the placebo-
controlled study. When this design is used, the Kampo
diagnosis is performed for all patientsbefore randomization,
although it is only needed for the group that actually receives
Kampo.
The ﬁrst design is that Kampo diagnoses and an
appropriate treatment could be used for stratiﬁcation within
the randomization process (see Figure 1). This design is
especially useful for pilot trials or smaller studies to prove
Kampo as an individualized treatment system. This trial
design allows for an individual Kampo treatment according
to the Kampo diagnosis. However, it also means that a
range of diﬀerent formulae will be administered. In order to
ensure blinding,itmight benecessary topreparean adequate
placebo for each formula, if they diﬀer in appearance, smell
and taste. In this type of trial, the patients should not
only be blinded for the treatment, but they should also
not receive any information about their Kampo diagnosis.
Designs like this have already been used for homeopathy
[157].
For many Western diagnoses, more than two Kampo
diagnoses are common. Diﬀerent patterns would result in a
larger number of subgroups and some of these might be too
small to have enough statistical power for subgroup analysis.
For this reason, it makes sense to use the pooled patterns
for primary analysis and to pre-specify subgroup analysis
for the more common patterns. Another possibility, which
might be easier to handle for the trial process, is to use
the Kampo diagnosis as additional inclusion criteria and to
recruit only those patients with relevant Kampo diagnosis
for the formula under research. An example for this can
be seen in the study by Kobayashi [158]. When using this
d e s i g n ,i tm u s tb er e c o g n i z e dt h a tal a r g en u m b e ro fp a t i e n t s
may need to be screened. In addition, the results are less
representative for the Western diagnosis and integration into
conventional care might be more diﬃcult, because WesternEvidence-Based Complementary and Alternative Medicine 13
Placebo
Placebo 2 (n = 50)
Placebo 1 (n = 50)
Kamishoyosan (n = 50)
Qi stagnation/depression pattern (n = 100)
Keishibukuryogan (n = 50)
Stagnant blood pattern (n = 100)
Verum
Kampo diagnosis and
treatment deﬁned
Randomization Treatment
Western inclusion and
exclusion criteria
ICD
N95.1
Figure 1: Combiningthe Western andKampo diagnosisfor a placebo-controlled trial: to evaluate the eﬃcacy of Kampo drug treatment, for
example, for menopausal symptoms (ICD N95.1).
Standard
Placebo 1 (n = 100)
Kamishoyosan (n = 50)
Diagnosis: qi stagnation/depression pattern
Treatment: Keishibukuryogan (n = 50)
Diagnosis: stagnatant blood pattern
Kampo
Kampo diagnosis
Randomization
Western inclusion and
exclusion criteria
n = 100
n = 100
ICD N95.1
Figure 2: Combining the Western and Kampo diagnosis for a standard care controlled trial: to evaluate the eﬀectiveness of Kampo as a
whole treatment system, for example, for menopausalsymptoms (ICD N95.1).
trained doctors could not diﬀerentiate between the diﬀerent
Kampo diagnoses.
3.3. Testing for Non-Inferiority or Superiority over Standard
Care. Doctors and patientswant toknowwhether it is better
to use Kampo instead of, or in addition to conventional
treatment. Depending on its causality or external validity,
the main focus of these studies could be performed more
experimentally (homogenous patients and clearly deﬁned
treatment protocols) or more pragmatically (heterogeneous
patients and a treatment which represents usual care)
[159]. Especially for chronic diseases where a more complex
treatment is needed [160], a pragmatic study design to test
Kampo as an additional treatment could provide useful
information for decision making. Similarly for the suggested
placebo-controlled study designs, it is possible to use an
individualized Kampo treatment within these studies.
The second possibility is to see the diagnostic procedure
as part of the Kampo treatment, and the diagnostic proce-
dure be used only on the Kampo group after randomization
Figure 2.S t u d yd e s i g n ss h o w ni nF i g u r e s1 and 2 are used to
answer diﬀerent research questions. The ﬁrst option focuses
on the treatment eﬀects of the drug, whereas the second
option provides a broader picture and evaluates Kampo
as a whole treatment system, which consists of both the
diagnostic procedure and the drug treatment.
3.4. Taking Patient Expectations into Account. Patient pref-
erences and patient expectation can play a role in com-
plementary and alternative medicine trials. Two systematic
reviews suggest that the inﬂuence of patient expectations
on outcomes is related to both within-group changes and
between-group diﬀerences [161, 162]. This has already been
shown for acupuncture [163]. If the patients in a Kampo14 Evidence-Based Complementary and Alternative Medicine
trial have higher expectations of a positive outcome than
the “average” patient, then this could result in within-
group changes that are larger than in a more representative
sample. High expectations might also be associated with
high response rates and improved outcomes in the placebo-
controlled group. This could result in a ceiling eﬀect making
it more diﬃcult to detect a signiﬁcant diﬀerence between
verum and placebo. Diﬀerent strategies are available to
deal with this problem, such as: including a run-in phase,
stratiﬁcation for randomization and measuring expectation.
A simple tool for measuring aspects of expectations at
baseline is to ask questions such as: “How eﬀective do you
expect the treatment to be?” with responses such as “very
eﬀective”, “eﬀective”, “slightly eﬀective”, “not eﬀective” or
“don’t know”. These data could be used to make adjustments
in the primary data analysis.
4.Conclusion
Kampo is a holistic and individualized treatment with a long
tradition and future research is required to take this into
account. RCT is the appropriate study design for testing
eﬃcacy or eﬀectiveness, however within such a study, the
treatment should be individualized according to the Kampo
diagnosis.
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